Amgen stock gains on Novo Nordisk's weightloss drug blunder

Amgen stock gains on drug results of Novo Nordisk.
Novo Nordisk's CagriSema drug reduced testings subjects' weight less than expected.
Amgen itself has struggled with developing its MariTide weightloss drug.
AMGN stock has been in a downtrend since at least July.

Clay Webster FXStreet

Amgen stock gained more than 2% in Friday’s morning session after foreign weightloss drug competitor Novo Nordisk (NVO) plunged following the results of new drug testing. As one of the leaders in weightloss pharmaceuticals, the news led other pharma stocks to run higher.

The Dow Jones Industrial Average (DJIA) index surged 1.8%, its best outing in awhile and especially after its historic ten-session pullback ended on Thursday by a hair. The DJIA is leading the NASDAQ and S&P 500 moderately at the time of writing.

The US Personal Consumption Expenditures (PCE) report for November is also cheering stock investors after Wednesday and Thursday witnessed widespread negativity over the Fed’s hawkish outlook. US inflation in the PCE arrived lower than economists had projected, which may mean that the Fed’s worries over inflation are likely to clear up in subsequent reports.

Amgen stock news

Novo Nordisk, the Danish maker of the Wegovy and Ozempic weightloss drugs, released data on the third phase of testing for its new CagriSema drug. CagriSema is supposed to be its next-generation drug for weightloss.

However, the data showed that CagriSema caused users to lose 20% of their weight after 68 weeks. This was in line with existing weightloss medicines and well below the 25% guidance that Novo Nordisk had previously aimed for.

Eli Lilly’s (LLY) Zepbound already reduces weight among its users by 23%, according to similar testing. Since the weightloss drug industry is expected to grow to $150 billion annually by 2030, the competitive nature of the sector has pushed up the competitors to Novo Nordisk.

One of those competitors is Amgen, which has been testing the MariTide drug for the same purpose. The company released test results in late November that showed the drug caused weight loss of up to 20% in obese and overweight individuals over a 52-week period. However, the results also showed that it might be causing patients to lose bone mineral density.

Amgen stock forecast

Amgen’s Thursday low of $253.30 was its lowest price since October 31, 2023, but the pharma stock rode an afternoon wave of optimism to produce a near 1% gain by the close. Friday is confirmation that the mood has changed.

Shares have risen back above the $261 level that acted as support on a number of occasions in late 2023 and throughout 2024. If AMGN stock can retain this region above $261, then the worst may be over. Shares of the pharmaceutical corporation have been trending lower since achieving an all-time high in July of this year above $346.

Still, lows created on November 26 and December 19 below $261 lead us to believe that the bottom may not be in. A third break below $261 will have many traders expecting the stock to dump all the way to the May through July 2023 lows in the demand zone stretching from $211 to $218.

AMGN daily stock chart

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to Premium Sign In

Author

Clay Webster

FXStreet

Clay Webster grew up in the US outside Buffalo, New York and Lancaster, Pennsylvania. He began investing after college following the 2008 financial crisis.

EUR/USD looks to stabilize near 1.1600 as focus shifts to US data

EUR/USD is looking to stabilize near 1.1600 in the European session on Wednesday as traders breathe a sigh of relief before the top-tier US ADP jobs and ISM Services PMI data. A pause in the US Dollar uptrend helps the pair's recovery, but surging energy prices due to the Iran war will likely remain a drag.

GBP/USD stays weak near 1.3350 as USD preserves gains

GBP/USD stays in the red below 1.3350 in the European session on Wednesday. Escalating conflict in the Middle East keeps the "flight to safety" theme intact, supporting the US Dollar against the Pound Sterling. Traders will take more cues from the US ADP Employment and ISM Services Purchasing Managers Index reports, which are due later on Wednesday.

Gold retains positive bias amid sustained safe-haven flows and modest USD pullback

Gold maintains its offered tone through the first half of the European session, though it lacks follow-through and remains below the $5,200 mark. Investors remain concerned about a prolonged conflict in the Middle East and its impact on the global economy amid an already uncertain environment.

Bitcoin, Ethereum and Ripple struggle for direction as consolidation persists

Bitcoin, Ethereum and Ripple prices trade with a cautious tone at the time of writing on Wednesday as upside momentum continues to fade across the broader crypto market. BTC remains within a parallel channel, ETH struggles below key resistance, while XRP remains fragile within a descending channel. These top three cryptocurrencies by market capitalization continue to struggle to establish a directional bias amid the consolidation phase.

Asian stocks fall as South Korea’s KOSPI slumps over 10%

Asian equities drop on Middle East tensions; the MSCI Asia Pacific Index falls up to 4%. South Korea’s KOSPI fell 10.71% near 5,170, with the Korean Won weakened past 1,500 per dollar.

Solana Price Forecast: SOL consolidation near resistance as ETF inflows offer mild support

Solana price is facing slight rejection as it approaches the upper boundary of the consolidation range at around $88 on Wednesday. Institutional demand is strengthening as spot Exchange Traded Funds recorded two consecutive inflows so far this week.